NASDAQ:RGEN Repligen (RGEN) Stock Forecast, Price & News $167.12 -0.80 (-0.48%) (As of 02:27 PM ET) Add Compare Share Share Today's Range$163.07▼$168.0050-Day Range$145.15▼$180.3152-Week Range$137.65▼$262.26Volume336,754 shsAverage Volume570,849 shsMarket Capitalization$9.31 billionP/E Ratio56.65Dividend YieldN/APrice Target$208.56 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Repligen MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside27.2% Upside$208.56 Price TargetShort InterestBearish10.24% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment1.23Based on 3 Articles This WeekInsider TradingAcquiring Shares$158,665 Bought Last QuarterProj. Earnings Growth27.43%From $2.37 to $3.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.86 out of 5 starsMedical Sector247th out of 1,980 stocksBiological Products, Except Diagnostic Industry35th out of 330 stocks 3.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $208.56, Repligen has a forecasted upside of 27.2% from its current price of $164.02.Amount of Analyst CoverageRepligen has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.24% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Repligen has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 69.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.30. Previous Next 2.4 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Repligen this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $158,665.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions91.00% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 27.43% in the coming year, from $2.37 to $3.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 55.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 55.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.88.Price to Earnings Growth RatioRepligen has a PEG Ratio of 3.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repligen (NASDAQ:RGEN) StockRepligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.Read More Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesMay 28, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives $208.56 Consensus Target Price from BrokeragesMay 23, 2023 | fool.comRepligen (NASDAQ: RGEN)June 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 22, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Repligen (NASDAQ:RGEN)May 16, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Hold Rating for Repligen (RGEN)May 11, 2023 | americanbankingnews.comInsider Buying: Repligen Co. (NASDAQ:RGEN) Director Buys $80,575.00 in StockMay 10, 2023 | msn.comLooking Into Repligen's Return On Capital EmployedMay 10, 2023 | americanbankingnews.comMartin D. Madaus Purchases 500 Shares of Repligen Co. (NASDAQ:RGEN) StockJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 9, 2023 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q1 2023 Earnings Call TranscriptMay 7, 2023 | americanbankingnews.comSVB Leerink Research Analysts Reduce Earnings Estimates for Repligen Co. (NASDAQ:RGEN)May 7, 2023 | americanbankingnews.comFY2023 EPS Estimates for Repligen Co. Boosted by Analyst (NASDAQ:RGEN)May 7, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for Repligen Co.'s Q2 2023 Earnings (NASDAQ:RGEN)May 6, 2023 | americanbankingnews.comBenchmark Trims Repligen (NASDAQ:RGEN) Target Price to $210.00May 6, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Repligen Co.'s Q3 2023 Earnings (NASDAQ:RGEN)May 6, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Decreased by AnalystMay 5, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) Updates FY23 Earnings GuidanceMay 5, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) Price Target Cut to $165.00 by Analysts at Deutsche Bank AktiengesellschaftMay 5, 2023 | americanbankingnews.comCraig Hallum Lowers Repligen (NASDAQ:RGEN) Price Target to $207.00May 5, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) PT Lowered to $210.00May 4, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Expected to Earn Q2 2023 Earnings of $0.54 Per ShareMay 4, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) Price Target Cut to $157.00 by Analysts at Royal Bank of CanadaMay 3, 2023 | finance.yahoo.comQ1 2023 Repligen Corp Earnings CallMay 2, 2023 | finance.yahoo.comRepligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial GuidanceMay 2, 2023 | finance.yahoo.comRepligen (RGEN) Surpasses Q1 Earnings and Revenue EstimatesMay 2, 2023 | finance.yahoo.comIs Repligen Corporation (RGEN) a Best-In-Class Stock in Terms of Growth and Profitability?May 1, 2023 | americanbankingnews.comRepligen (RGEN) Scheduled to Post Earnings on TuesdaySee More Headlines RGEN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Company Calendar Last Earnings5/02/2023Today6/01/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees2,025Year Founded1981Price Target and Rating Average Stock Price Forecast$208.56 High Stock Price Forecast$275.00 Low Stock Price Forecast$157.00 Forecasted Upside/Downside+27.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.95 Trailing P/E Ratio55.28 Forward P/E Ratio68.81 P/E Growth3.05Net Income$185.96 million Net Margins21.58% Pretax Margin25.24% Return on Equity9.14% Return on Assets6.87% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio1.91 Sales & Book Value Annual Sales$801.54 million Price / Sales11.33 Cash Flow$4.09 per share Price / Cash Flow39.87 Book Value$34.85 per share Price / Book4.68Miscellaneous Outstanding Shares55,680,000Free Float55,068,000Market Cap$9.08 billion OptionableOptionable Beta1.08 Social Links Key ExecutivesTony J. HuntPresident, Chief Executive Officer & DirectorJames R. BylundChief Operating OfficerJon K. SnodgresChief Financial & Accounting OfficerRalf KuriyelSenior Vice President-Research & DevelopmentVikas GuptaVP & GM-Downstream Bioprocessing & Gene TherapyKey CompetitorsNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOSeagenNASDAQ:SGENQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 893 shares on 5/26/2023Ownership: 0.006%Legato Capital Management LLCSold 3,314 shares on 5/25/2023Ownership: 0.009%Royce & Associates LPSold 81,700 shares on 5/23/2023Ownership: 0.019%Toroso Investments LLCBought 155 shares on 5/23/2023Ownership: 0.004%Ameriprise Financial Inc.Sold 19,337 shares on 5/22/2023Ownership: 1.913%View All Insider TransactionsView All Institutional Transactions RGEN Stock - Frequently Asked Questions Should I buy or sell Repligen stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price forecast for 2023? 8 Wall Street research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price forecasts range from $157.00 to $275.00. On average, they predict the company's stock price to reach $208.56 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2023? Repligen's stock was trading at $169.31 at the start of the year. Since then, RGEN stock has decreased by 3.7% and is now trading at $163.07. View the best growth stocks for 2023 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.05. The biotechnology company earned $182.70 million during the quarter, compared to analyst estimates of $181.43 million. Repligen had a trailing twelve-month return on equity of 9.14% and a net margin of 21.58%. Repligen's revenue was down 11.5% compared to the same quarter last year. During the same period last year, the business posted $0.92 EPS. What ETFs hold Repligen's stock? ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Invesco Dynamic Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG), WisdomTree BioRevolution Fund (WDNA) and BlackRock Future Health ETF (BMED). What guidance has Repligen issued on next quarter's earnings? Repligen issued an update on its FY23 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.35-$2.42 for the period, compared to the consensus estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.76%), State Street Corp (2.94%), Sands Capital Management LLC (2.90%), Wellington Management Group LLP (2.68%), Brown Capital Management LLC (2.59%) and Artisan Partners Limited Partnership (2.19%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $163.07. How much money does Repligen make? Repligen (NASDAQ:RGEN) has a market capitalization of $9.08 billion and generates $801.54 million in revenue each year. The biotechnology company earns $185.96 million in net income (profit) each year or $2.95 on an earnings per share basis. How many employees does Repligen have? The company employs 2,025 workers across the globe. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115. This page (NASDAQ:RGEN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.